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were found to have had non-focal symptoms or migraines. Two pts were considered to 
have had a TIA with the mechanism being possible cardio-embolic and I-pt had a non- 
cardio-embolic stroke due to an alternative ischemic source (ulcerated carotid plaque). 
Overall, 2/142 pts (1.4%) suffered a possible cardio-embolic neurologic event at latest 
follow-up. Conclusion: These data indicate that TC device PFO closure is safe and 
effective in preventing recurrent paradoxical embolism and should be considered an 
alternate therapy to life-long pharmacoligic therapy or surgical closure. In our patient 
population the risk of a potential recurrent neurologic event was low with no pt having a 
recurrent stroke without an alternative ischemic source. 
1021-161 Cardiopulmonary Exercise Capacity Increases in 
Patients With Atrial Septal Defect Following 
Transcatheter Closure 
Michael W. Weber, Thomas Neumann, Matthias Ftau. Christian Maikowski, Torsten Dill, 
Roland R. Brandt, Vesselin Mitrowc, Christian Hamm. Kerckhoff Heart Centre, Bad 
Nauheim, Germany 
Background: Atrlal septal defect (ASD) of the secundum is the most common congenital 
heart disease in adults. Generally closure is recommended in symptomatic patients and 
in patients with a large left to right shunt (Qp/Qs > 1.5). Only few data exists about 
improvement in exercise capacity after ASD closure. Objective of this study was to eval- 
uate exercise capacity as achieved by ergospirometly in adult patients with an ASD of 
the secundum at baseline and following transcatheter closure. 
Methods: 30 consecutive patients ( 9 male; aged 43*15 years; defect size 23 f 4,23mm; 
pulmonary-to-systemic flow ratio (QpIQs) 2.0 f 0.9; mean pulmonary ariely pressure 16 
f 4,3 mm Hg) performed exercise testing on a supine bicycle ergometer. Maximal oxy- 
gen consumption (VO, max) and oxygen consumption at the anaerobic threshold (VO, - 
AT) were assesed at baseline, 1 month and 12 month after ASD closure (Ergospirometer 
Fa. Jaeger, Germany). For ASD closure an Amplatzer - occludsr (AGA medic&, Minne- 
sota, USA) was used. 
Results: MaxImal oxygen consumption (VO, max) was reduced at baseline 14,l * 3,9 
mUminlkg with an increase after 1 month to 14,3 + 4.0 mVminlkg (n.s.) and after 12 
month to 14,9 f 4,0 mllminlkg (p < 0,05). Oxygen consumption at the anaerobic thresh- 
old (VO, - AT) was at baseline 11.1 f 2,7 mllminikg with an increase after 1 month to 
11.6 * 28 mlJmin/kg (ns.) and after 12 month to 12,6 * 3.1 mllminlkg (p < 0.01). Work 
load increased from 62 f 26 watt to 66 * 29 watt (n.s.) after 1 month and to 92 * 29 watt 
( p < 0,Ol) after 12 month. Improvement in exercise capacity (A VO, - AT) was not corre- 
lated to defect size, pulmonary-to-systemic flow ratio or mean pulmonary artery pressure 
before ASD closure. 
Conclusion: Exercise capacity of adult patients presenting with an ASD of secundum 
was reduced at baseline. Early after hanscatheter closure (1 month) there was no rele- 
vant increase in exercise capacity, but late after ASD closure (12 month) exercise capac- 
ity has increased significantly. These findings emphasize the benefit of intewentional 
ASD closure in adult patients. 
1021-162 Relief of Migraine Headaches Associated With Closure 
of Patent Foramen Ovale 
Mark Reisman, William A. Gray, John V. Olsen, Swedish Cardiovascular Research, 
Seattle, WA 
Background: Previous reports have documented that the incidence of PFO in the 
migraine patient population is at least twice that of the general population. However few 
reports demonstrate the potential impact of PFO closure on the relief of migraine head- 
aches. Recently introduced percutaneous closure devices for treating patent foramen 
wale (PFO) provide a low-risk and effective alternative to surgical closure or chronic 
warfarin therapy in patients with paradoxic emboli and stroke. 
Methods: Between 4101 and 7102 69 PFOs were closed usma the NMT Cardweal 
device for patients with a history of prior TIA or stroke. All patients had positive transcra- 
nial Doooler (TCDl and oositive contrast transthoracic echo 1cTTE) or transesoohaaeal 
(cTEE) studies. Tisting ‘for PFO closure was obtained at 1, ‘3, anb 6 months dy c?CD 
and cTTE or until complete closure was identified. Once closure was documented, all 
patients completed a questionnaire to identify the presence, frequency and type of 
migraine headache (MH) episodes occurring pre- and post-procedure. MH, and associ- 
ated aura were defined according to the criteria of the International Headache Society. 
Patients were not informed that PFO closure might have any impact on MH prior to pro- 
cedure. 
Results: Among our total of 69 PFO closures during this interval, 16 (26 %) patients had 
MH and 14/16 had aura. The average age of MH patients was 44 years and 55% were 
female. Percutaneous closure was successful in 16 patients and 2 patients were closed 
surgically. Follow-up studies showed complete PFO closure in all patients. 1 patient was 
lost to follow-up. Of the patients with successful closure 7 (36%) had complete relief of 
MH and 6 (44%) had partial relief. There was a cumulative reduction in frequency of MH 
from 3.06 episodeslptlmonth to .05 episodeslptlmonth. 
Conclusion: This observational study demonstrated that PFO closure can reduce, and 
frequently eliminate, migraine episodes and suggests that in some patients with MH, 
PFOs may have a role in the genesis of headache. The RELIEF registry will study this 
population further. 
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1046-l 55 Influence of Pacemaker Lead Localization on 
Reintervention Rate in Children 
Rainer Schrepf, Manfred Vogt, Viola Helming, Christoph Kolb, John Hess, Medical Clinic 
of the University of Munich lnnenstadt, Munich, Germany, German Heart Center 
Munich, Munich, Germany 
Pm-studies in our institution m 1996 showed an increased (e-intervention rate, a reduced 
pacemaker longevity respectively in epicardial lead positioning (4.1~2.6~. median 3.7~) 
when compared to the transvenous approach (6.4*1.6y, mizdian 6.5~) (p-zO.009) in chil- 
dren. This is mainly due to an increase I” pacing and sensing thresholds. The propoltion 
between epicardial and endocardial leads was 3:i (45 vs.15 patients). We therefore 
changed our standard approach to transvenous Implantation where applicable in 1997. 
We included all 51 consecutive children that were implanted between 1.1.1997 and 
31.12.2001 in our institution into our follow-up study. 25 patients obtained transvenous 
lead implantation, 26 had to be provided with epicardial leads due to the underlying heart 
disease and performed cardiac surgery or limitations in age, weight or size of the chil- 
dren. 29 were male (57%), 22 were female (43%). Mean age at implantation was 
6.7*7.2y, median 7.9y (p < 0.05 compared to the previous period), size and weight did 
not differ significantly The smallest child to obtain an epwardial pacing system had two 
days, minimum weight was 2.6kg compared to 10 months and 7.6kg in the sndocardial 
group. Comparing the patient population before and after 1997 the number of dual cham- 
ber pacemakers increased from n=4 (7%) (until 1996) to n=30 (59%) (from 1997) signifi- 
cantly (p < 0.001). The use of atrial leads increased from 6 to 31 whereas the percentage 
of endocardial applications remained stable without signifwmt difference. The percent- 
age of endocardial ventricular leads increased significantly (p = 0.006) from 23 (n=l3) to 
46 (n=24). 
9 of the 26 patients with epicardial leads had a m-intervention compared to 6 of the 25 
children with a transvenous system (p = II.?..). The mean time to re-intervention did not 
differ significantly in both groups (epi: l.O+l.ly vs. endo: 0.3+0.3y). 
Conclusion: The usage of transvenous endocardial leads and dual chamber systems in 
children is safe and well tolerated without increase in complication rate. Cut of in age and 
weight for the extensive application of transvenous leads in our patient population was 
roughly one year and 10 kg. 
1046-156 Magnetic Resonance Imaging and the Diagnosis of 
Right Ventricular Dysplasia in Children: An Institutional 
Experience 
Mark A. Foael, Paul M. Weinberg, Larry Rhodes, Children’s Hospital of Philadelphia, 
Philadelphia, PA, University of Pennsylvania School of Medicine, Philadelphia, PA 
Background: Magnetic resonance imaging (MRI) has been helpful in adults to diagnose 
of right ventricular (RV) dysplasia. Short of direct observation, no gold standard exists. 
Diagnostic criteria by MRI includes right atrial and ventrwlar dilation, regional RV wall 
motion abnormalities, RV outflow tract ectasia and RV myocardial fatty infiltration. Meth- 
ods: To determine whether these diagnostic criteria are useful in children referred for 
cardiac MRI. the images and records of 44 patients over an 7 year period from our insti- 
tution were reviewed. Referral diagnoses included a history of ventricular tachycardia. 
palpitations, syncope, near sudden death or a family history of RV dysplasia. 4 families 
were studied with parents who had RV dysplasia diagnosed by surgery, explanted heart, 
or MRI. MRI imaging included Tl images with and without fat saturation, tine MRI. l- 
dimensional myocardial stripes of the RV, and phase encoded velocity mapping. 
Results: None of the 44 patients met more than 2 of the criteria and only 2 patients met 
one or 2 criteria. For questionable regional wall motion abnormalities, l-dimensional 
myocardial tagging was able to identify normal myocardial shortening. Conclusions: 
Cardiac MRI on children with a h&tory suspicious of RV dysplasia is a low yield test. This 
may be due to evolving nature of the disease which does not manifest itself from a mor- 
phologic or ventricular function standpoint until later on in development. Follow-up stud- 
ies as the patients age may be advantageous. 
